The German Thorotrast Study: Recent Results and Assessment of Risks
The DOI matches its Crossref record.
Abstract
The German Thorotrast study comprises 2,326 patients and 1,890 controls. Forty-eight Thorotrast patients and 239 controls are still alive and are invited for a follow-up examination every 2 years. In the deceased patients, the following neoplastic diseases with excess rates were registered (Thorotrast/controls): liver cancer (454/3); cancer of the bile ducts, including gallbladder (42/7); myeloid leukemia (40/7); myelodysplastic syndrome (30/4); plasmacytoma (10/2); non-Hodgkin's lymphoma (15/5); bone sarcoma (4/1); malignant peritoneal or pleural mesothelioma (9/0). Dose calculations are based on results of whole-body counting, X-ray films, and data obtained from the hospital records on the volume of Thorotrast injected. For liver cancer, the cumulative risk estimate was calculated to be 40 per 10(4) person Sv (radiation weighting factor = 20). These figures are close to the results of the Danish study and are comparable to the results of the Life Span Study of A-bomb survivors after 40 years at risk with 18 to 48 liver cancers per 10(4) person Sv. For hematopoietic malignancies, the cumulative risk was calculated to be about 7 per 10(4) person Sv (radiation weighting factor = 20). This risk estimate is lower by a factor of 10 compared to the results of the Life Span Study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Advances in Malignant Mesothelioma
Robinson, B. W. S., & Lake, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050152 · Cited by 889
Valentin, J. (2003) · Annals of the ICRP · doi:10.1016/s0146-6453(03)00024-1 · Cited by 521
The Linear No-Threshold Relationship Is Inconsistent with Radiation Biologic and Experimental Data
Tubiana, M., Feinendegen, L. E., Yang, C., & Kaminski, J. M. (2009) · Radiology · doi:10.1148/radiol.2511080671 · Cited by 509
CANCER RISKS FROM MEDICAL RADIATION
Ron, E. (2003) · Health Physics · doi:10.1097/00004032-200307000-00011 · Cited by 382
“Epidemiologic follow-up studies of thousands of patients injected with Thorotrast consistently show high risks of liver disease, cancer, and leukemia (dos Santos Silva et al. 1999; Mori et al. 1999; van Kaick et al. 1999; Travis et al. 2001; Nyberg et al. 2002).”
BackgroundThe non-Hodgkin lymphomas: A review of the epidemiologic literature
Alexander, D. D., Mink, P. J., Adami, H.-O., Chang, E. T., Cole, P., Mandel, J. S., & Trichopoulos, D. (2007) · International Journal of Cancer · doi:10.1002/ijc.22719 · Cited by 343
Multiple myeloma: A review of the epidemiologic literature
Alexander, D. D., Mink, P. J., Adami, H.-O., Cole, P., Mandel, J. S., Oken, M. M., & Trichopoulos, D. (2007) · International Journal of Cancer · doi:10.1002/ijc.22718 · Cited by 321
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
Bibby, A. C., Tsim, S., Kanellakis, N., Ball, H., Talbot, D. C., Blyth, K. G., Maskell, N. A., & Psallidas, I. (2016) · European Respiratory Review · doi:10.1183/16000617.0063-2016 · Cited by 316
Epidemiology of peritoneal mesothelioma: a review
Boffetta, P. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl345 · Cited by 309
Tubiana, M. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.12.016 · Cited by 280
A Review and Update on Cholangiocarcinoma
Olnes, M. J., & Erlich, R. (2004) · Oncology · doi:10.1159/000077991 · Cited by 266
Mesothelium and Malignant Mesothelioma
Hiriart, E., Deepe, R., & Wessels, A. (2019) · Journal of Developmental Biology · doi:10.3390/jdb7020007 · Cited by 66
“Radiation: Exposure to ionizing radiation or sequelae following pleural infection (chronic inflammation) has also been reported to play a role in the subsequent occurrence of MPM [4,182].”
Background
Metadata
- Authors
- van Kaick, G., Dalheimer, A., Hornik, S., Kaul, A., Liebermann, D., Lührs, H., Spiethoff, A., Wegener, K., Wesch, H., & Luhrs, H.
- Venue
- Radiation Research
- Publisher
- JSTOR
- Published
- 1999-12
- Volume
- 152
- Issue
- 6
- Pages
- S64
- ISSN
- 0033-7587 (ISSN-L)
- OpenAlex
- W2330671117
- Cited by
- 99
- References
- 0
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.